Paris – November 18, 2022 – Medical Devices Venture announces that its subsidiaries Dextrain and Poladerme have obtained in May 2022 and November 2022 the BPI Deep tech label and the French Tech Emergence grant (BFTE) for an amount of 90,000 euros in order to finance their disruptive innovation projects resulting from academic research.


Dextrain develops breakthrough solutions targeting the analysis and rehabilitation of post-stroke dexterity. Impairment of neuromotor function in the hands has a major impact on the quality of life of people who have had a stroke. Dextrain’s solutions provide an objective measurement of deficits and rehabilitation solutions aimed at restoring better dexterity in everyday life. In the hospital or in care centers but also at home. More information on


More than a third of the world’s population suffers from skin problems of varying severity (acne, shingles, psoriasis, eczema, herpes, lupus, dermatitis, melanoma, carcinoma) and the environmental impact exacerbates these problems.

Poladerme is developing a device that combines the functions of a connected dermascope with spectro-polarimetry and artificial intelligence to quickly analyze lesions and skin quality indices. These disruptive technologies exploit high-quality imaging data in a secure workflow and based on innovative processing algorithms. More information on:

Catégories : News Room